Advanced breast cancer: This guideline updates and replaces NICE technology appraisal guidance 62 (capecitabine), 54 (vinorelbine) and 30 (taxanes)

Breast Cancer: Prognosis, Treatment, and Prevention Second Edition

609 p | 68 | 11

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER2−metastatic or advanced breast cancer patients: A network meta-analysis

12 p | 5 | 3

Real-world safety of palbociclib in breast cancer patients in the United States: A new user cohort study

13 p | 13 | 1

Trastuzumab in advanced breast cancer – a decade of experience in Germany

9 p | 12 | 1

Patterns of resource utilization and cost for postmenopausal women with hormonereceptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

12 p | 18 | 1

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: Results of the prospective observational EvAluate-TM study

9 p | 11 | 1

Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes

13 p | 10 | 0

ESR1 PvuII polymorphism: From risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer

7 p | 16 | 0

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol

5 p | 11 | 0